ADL Amdl,

TUSTIN, Calif., May 21 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL) announced today that for the three-month period ended March 31, 2007 the Company had net revenue of $1,424,179 (unaudited), gross profits of $726,869 (unaudited) and an operating loss of ($1,385,406) (unaudited). For Jade Pharmaceutical Inc., ("JPI"), net revenues increased to $1,410,029 (unaudited) for the three month period ended March 31, 2007, a 16 percent increase when compared to the same period last year. Net profit was $124,337 (unaudited) for the three months ended March 31, 2007. Please see a copy of the Company's 10-QSB filed on May 21, 2007 for more details. Mr. Gary Dreher, CEO of AMDL stated that, "As noted in the last two press releases AMDL's subsidiary JPI, continues to grow its marketing and sales footprint in the China market. These activities position JPI for increased sales growth, particularly during the second half of 2007. Based upon the recently signed distribution agreements and discussions between JJB and its new distribution partners, there is a potential to increase JPI's sales in Southern China and the Shanghai regional markets by as much as (US) $16 million over the next 12 month sales cycle". About AMDL: AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. ("JPI"), is an international biopharma company. AMDL together with JPI, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. More information about AMDL and its products can be obtained at http://www.amdl.com/. About JPI: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice ('CGMP') standards. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright